Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Psyence BiomedicalPBM +9.64%14 Equity-to-Asset is 0.97 as of Mar. 2026, which is 5% above its 10-year median of 0.92. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,413 Biotechnology companies, Psyence Biomedical ranks better than 97.66% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Psyence Biomedical Equity-to-Asset Related Terms
Psyence Biomedical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Psyence Biomedical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBM vs NRSN, PLUR, CALC: Equity-to-Asset Comparison
For the Biotechnology subindustry, Psyence Biomedical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Psyence Biomedical Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Psyence Biomedical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Psyence Biomedical's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Psyence Biomedical (PBM) has a Equity-to-Asset of 0.97 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Psyence Biomedical and its competitors. This is near median its historical median of 0.92. According to the industry distribution chart, Psyence Biomedical ranks #33 out of 1413 companies in the Biotechnology industry, placing it in the top 2.3%.
Is Psyence Biomedical's Equity-to-Asset too high?
Psyence Biomedical's current Equity-to-Asset of 0.97 is near median its 10-year median of 0.92. The Biotechnology industry median Equity-to-Asset is 0.69. Psyence Biomedical's value of 0.97 is 40.6% above this industry median. Based on the distribution chart, Psyence Biomedical ranks #33 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's Equity-to-Asset compare to NRSN and PLUR?
According to the Biotechnology industry distribution chart, Psyence Biomedical ranks #33 out of 1413 companies for Equity-to-Asset. This places Psyence Biomedical in the top 2% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.69. Psyence Biomedical's value of 0.97 is 40.6% above this benchmark. While the company's 10-year median is 0.92 vs. the industry median of 0.69, Psyence Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Psyence Biomedical's current Equity-to-Asset of 0.97 is 40.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Psyence Biomedical and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Psyence Biomedical's current Equity-to-Asset is 0.97, which is near median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current Equity-to-Asset of 0.97. The current Equity-to-Asset is 0.97, which is near median its 10-year median of 0.92 and 40.6% above the Biotechnology industry median of 0.69. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current Equity-to-Asset is 0.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score
Get the complete analysis for PBM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBM has been successfully added to your 
